Clinical Trials on Relapsed or Refractory Indolent Non-Hodgkin Lymphoma in Belgium

Total 241 results

Menarini Group

Terminated

MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study (CD205SHUTTLE)

Metastatic Solid Tumors | Relapsed/Refractory Non-Hodgkin Lymphoma

Italy, Spain, Belgium, United Kingdom
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

B-Cell Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin Lymphoma

United States, Spain, Italy, United Kingdom, Belgium, Czechia
SecuraBio

Completed

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)

Indolent Non-Hodgkin Lymphoma

Belgium, France, Italy, Spain, Canada, United States, Bulgaria, United Kingdom, Hungary, Georgia, Belarus, Czechia
Kite, A Gilead Company

Active, not recruiting

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Spain, United States, Czechia, Sweden, Germany, Belgium, Italy, Canada, France, Netherlands, Poland
Gilead Sciences

Completed

Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma (ZEUS)

Follicular Non-Hodgkin's Lymphoma Refractory

Spain, France, Ireland, Italy, Greece, Germany, United Kingdom, Sweden, Belgium, Portugal
Allogene Therapeutics

Active, not recruiting

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPAND)

Relapsed/Refractory Large B Cell Lymphoma

United States, Belgium
European Organisation for Research and Treatment...

Terminated

Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma

Lymphoma

Belgium
Hoffmann-La Roche

Active, not recruiting

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma

Belgium, Spain, Denmark, Italy, United Kingdom, Israel, United States
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
Bayer

Completed

Copanlisib Pharmacodynamic Study

Non Hodgkin Lymphoma

Belgium, France, United Kingdom
Hoffmann-La Roche

Completed

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, Follicular Lymphoma

United Kingdom, Belgium, United States, Australia, Canada, Germany
Epizyme, Inc.

Recruiting

Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma (SYMPHONY-1)

Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Refractory Follicular Lymphoma

United States, China, Spain, France, Taiwan, United Kingdom, Australia, Korea, Republic of, Canada, Italy, Hungary, Poland, Belgium, Germany
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
MorphoSys AG

Completed

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin Lymphoma

United States, Belgium, Germany, Hungary, Italy, Poland, Spain
Hoffmann-La Roche

Recruiting

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Belgium, Australia, Denmark, Spain, Taiwan, France, Italy, United States, Canada, Czechia, New Zealand, Poland, Finland
Celgene

Terminated

A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma (EXPECT)

T-cell Non-Hodgkin's Lymphoma

France, United States, Australia, Belgium
ADC Therapeutics S.A.

Terminated

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United States, Belgium, Hungary, Israel, Spain, Switzerland, Poland, France, United Kingdom, Italy
Pfizer

Completed

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

United States, Spain, France, Switzerland, United Kingdom, Belgium, Germany
The Lymphoma Academic Research Organisation

Active, not recruiting

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Aggressive Non-Hodgkin Lymphoma

France, Belgium
Novartis Pharmaceuticals

Recruiting

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

B-cell Non-Hodgkin Lymphoma (B-NHL) | B-cell Acute Lymphoblastic Leukemia (B-ALL)

Japan, Italy, Spain, Belgium, Singapore, France, United States, Israel
European Organisation for Research and Treatment...

Unknown

Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

Lymphoma | Leukemia

France, Belgium, Portugal
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Relapsed Hodgkin Lymphoma

United States, Spain, United Kingdom, Poland, Belgium, Hungary, Germany, France, Italy, Czechia, Canada
Amgen

Completed

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

B-Cell Non Hodgkin Lymphoma

United States, Spain, United Kingdom, Belgium, Italy, Australia, Canada, Puerto Rico
Bayer

Completed

A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

Lymphoma, Follicular | Non-Hodgkin Lymphoma

Belgium
Nordic Nanovector
ICON Clinical Research

Active, not recruiting

A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)

Follicular Lymphoma | Non-Hodgkin Lymphoma

United States, Korea, Republic of, Australia, Austria, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Singapore, Spain, Sweden, Switzerland, Turkey, United Kingdom
European Organisation for Research and Treatment...

Terminated

Involved-Field Radiation Therapy in Treating Patients With Previously Untreated Stage I or Stage II Low-Grade Non-Hodgkin's Lymphoma

Lymphoma

France, Belgium, Denmark, Egypt, Netherlands, Croatia
Novartis Pharmaceuticals
XOMA (US) LLC

Completed

Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

United States, Belgium, Canada, Italy, France, Hong Kong, Australia, United Kingdom, Singapore, Korea, Republic of, Germany
Cephalon

Completed

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma (NHL)

United States, Belgium, Israel
Incyte Corporation

Active, not recruiting

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Spain, France, Italy, Belgium, Germany, Austria
Hoffmann-La Roche
AbbVie

Completed

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

Follicular Lymphoma

United States, Italy, Canada, Australia, Belgium, United Kingdom, Germany, France
Sanofi

Terminated

Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma (GRAAL2)

Hyperuricemia

Germany, Belgium, Italy, France
Debiopharm International SA

Completed

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Diffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's Lymphoma

United States, Czechia, Bulgaria, Belgium, Hungary, Ukraine, Italy, Poland, Switzerland
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

United States, Canada, Belgium, Spain, United Kingdom
Cephalon

Completed

Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma

Solid Tumors or Mantle Cell Lymphoma

Belgium, France
Novartis Pharmaceuticals
GlaxoSmithKline

Terminated

Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy (HOMER)

Non-Hodgkin's Lymphoma

China, United States, Belgium, Czechia, France, Japan, Bulgaria, Canada, Hungary, Peru, Slovakia, South Africa, Ukraine, Korea, Republic of, Puerto Rico, Brazil
BeiGene

Recruiting

Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma (MCL)

United States, China, Israel, Belgium, Poland, Spain, Turkey, Brazil, Italy, Canada, United Kingdom, France, Germany, Argentina, Puerto Rico
Commissie Voor Klinisch Toegepast Onderzoek

Completed

Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

Netherlands, Belgium
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

France, United States, Spain, Korea, Republic of, Australia, Israel, India, Thailand, China, Czech Republic, Belgium, New Zealand, Russian Federation, Finland, South Africa, United Kingdom, Italy, Brazil, Hungary, Puerto Rico, A... and more
The Lymphoma Academic Research Organisation
Celgene

Active, not recruiting

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

Relapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell Lymphoma

France, Denmark, United Kingdom, Austria, Belgium
The Lymphoma Academic Research Organisation

Completed

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

France, Belgium
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Lymphoma

France, Netherlands, Belgium, United Kingdom, Egypt, Switzerland, Portugal
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Lymphoma

United States, Belgium, Japan, Korea, Republic of, Germany, Hong Kong, Hungary, Netherlands, Singapore
MEI Pharma, Inc.
Kyowa Kirin, Inc.

Terminated

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Follicular Lymphoma (FL)

United States, France, Spain, Korea, Republic of, United Kingdom, Belgium, Japan, Taiwan, Australia, Poland, Italy, Canada, Georgia, Greece, Hungary, Netherlands, New Zealand, Serbia, Turkey
Pfizer
UCB Pharma

Completed

Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

Korea, Republic of, Canada, Belgium, Singapore, United States, Hong Kong, Japan, United Kingdom, France
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

Relapsed/Refractory Follicular Lymphoma | Marginal Zone Lymphoma (MZL)

Korea, Republic of, Australia, France, Spain, Malaysia, Taiwan, Italy, Poland, United States, Turkey, Thailand, United Kingdom, Belgium, Czechia
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Hodgkin Lymphoma | Anaplastic Large-cell Lymphoma

Spain, Belgium, Lithuania
AbbVie

Recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | B Cell Malignancies

United States, Israel, Australia, France, United Kingdom, Belgium, Spain
Pfizer
UCB Pharma

Terminated

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Follicular

Belgium, United States, Canada, Hong Kong, Korea, Republic of, Portugal, Spain, Poland, India, Argentina, Italy, Mexico, Russian Federation, South Africa
Universitaire Ziekenhuizen KU Leuven

Unknown

Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma

Lymphoma | Hodgkin Lymphoma | Non-Hodgkin Lymphoma (Follicular, Diffuse B-cel Lymphoma, PTLD and Mantle Cel Lymphoma)

Belgium
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

B-Cell Lymphoma

United States, Belgium, Korea, Republic of, Switzerland, France, Poland, Spain, Hong Kong, Australia, Germany, Italy, Netherlands, United Kingdom

Clinical Trials on Relapsed or Refractory Indolent Non-Hodgkin Lymphoma in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations